MedPath

Atorvastatin at high dosage before coronary stent surgery: effect on peri-procedure miocardic stroke . - ND

Phase 1
Conditions
elective PCI in de novo coronaric lesions
MedDRA version: 6.1Level: SOCClassification code 10047065
Registration Number
EUCTR2007-005056-16-IT
Lead Sponsor
OSPEDALE S. RAFFAELE
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
700
Inclusion Criteria

1)age > or equal 18 yeras old; 2) no ongoing treatment with statine 3)new stenosis on native vassel
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1) pregnancy; 2) acute pulmonary edema ;3)acute miocardic stroke and/or acute coronaric syndrome; 4) high values of cardiac enzymes; 5) recent (2 days or more) acute miocardic stroke and/or acute coronaric syndrome; 6) patients enrolled in omgoing studies; 7) ongoing statine system; 8) chronic renal insufficiency in dialisis; 9) intollerance history to statine, ticopidina or clopidogrel; 10) ongoing treatment withglicoproteina IIbIIIa inhibitors;

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: efficacy evaluation of acute administration of Atorvastatin at high dose (80 mg) the day before surgery in prevention of peri-procedure stroke.;Secondary Objective: efficacy evaluation of acute administration of Atorvastatin at high dose (80 mg) the day before surgery in prevention of peri-procedure stroke.;Primary end point(s): efficacy evaluation of acute administration of Atorvastatin at high dose (80 mg) the day before surgery in prevention of peri-procedure stroke.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath